Medicare Program; Approval of Application by The Compliance Team for Initial CMS-Approval of Its Home Infusion Therapy Accreditation Program, 60799-60800 [2020-21260]
Download as PDF
Federal Register / Vol. 85, No. 188 / Monday, September 28, 2020 / Notices
State agencies consistent with
applicable statutory or regulatory
requirements (see 42 CFR 460.136(a)(5)).
Form Number: CMS–10525 (OMB
control number: 0938–1264); Frequency:
Annual; Affected Public: Private Sector:
Business or other for-profits; Number of
Respondents: 134; Total Annual
Responses: 1,143; Total Annual Hours:
173,664. (For policy questions regarding
this collection contact Donna
Williamson at 410–786–4647.)
3. Type of Information Collection
Request: Reinstatement; Title of
Information Collection: Establishment of
an Exchange by a State and Qualified
Health Plans; Use: The Patient
Protection and Affordable Care Act,
Public Law 111–148, enacted on March
23, 2010, and the Health Care and
Education Reconciliation Act, Public
Law 111–152, enacted on March 30,
2010 (collectively, ‘‘Affordable Care
Act’’), expand access to health
insurance for individuals and
employees of small businesses through
the establishment of new Affordable
Insurance Exchanges (Exchanges),
including the Small Business Health
Options Program (SHOP).
As directed by the rule Establishment
of Exchanges and Qualified Health
Plans; Exchange Standards for
Employers (77 FR 18310) (Exchange
rule), each Exchange will assume
responsibilities related to the
certification and offering of Qualified
Health Plans (QHPs). To offer insurance
through an Exchange, a health insurance
issuer must have its health plans
certified as QHPs by the Exchange. A
QHP must meet certain minimum
certification standards, such as network
adequacy, inclusion of Essential
Community Providers (ECPs), and nondiscrimination. The Exchange is
responsible for ensuring that QHPs meet
these minimum certification standards
as described in the Exchange rule under
45 CFR 155 and 156, based on the
Affordable Care Act, as well as other
standards determined by the Exchange.
The reporting requirements and data
collection in the Exchange rule address
Federal requirements that various
entities must meet with respect to the
establishment and operation of an
Exchange; minimum requirements that
health insurance issuers must meet with
respect to participation in a State based
or Federally-facilitated Exchange; and
requirements that employers must meet
with respect to participation in the
SHOP and compliance with other
provisions of the Affordable Care Act.
Form Number: CMS–10593 (OMB
Control Number: 0938–1312);
Frequency: Monthly, Annual; Affected
Public: Private Sector; Number of
VerDate Sep<11>2014
18:25 Sep 25, 2020
Jkt 250001
Respondents: 20; Number of Responses:
361; Total Annual Hours: 51,805. (For
policy questions regarding this
collection contact Courtney Williams at
301–492–5157.)
Dated: September 23, 2020.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2020–21384 Filed 9–25–20; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3386–FN]
Medicare Program; Approval of
Application by The Compliance Team
for Initial CMS-Approval of Its Home
Infusion Therapy Accreditation
Program
Centers for Medicare and
Medicaid Services, HHS.
ACTION: Final notice.
AGENCY:
This final notice announces
our decision to approve The
Compliance Team for initial recognition
as a national accrediting organization
for home infusion therapy suppliers that
wish to participate in the Medicare
program. A home infusion therapy
supplier that participates must meet the
Medicare conditions for coverage.
DATES: The approval announced in this
final notice takes effect October 1, 2020
through October 1, 2024.
FOR FURTHER INFORMATION CONTACT:
Christina Mister-Ward, (410) 786–2441.
Shannon Freeland, (410) 786–4348.
Lillian Williams, (410) 786–8636.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
Home Infusion therapy (HIT) is a
treatment option for Medicare
beneficiaries with a wide range of acute
and chronic conditions. Section 5012 of
the 21st Century Cures Act (Pub. L. 114–
255, enacted on December 13, 2016)
added sections 1861(iii) and 1834(u) to
the Social Security Act (the Act),
establishing a new Medicare benefit for
HIT services. Section 1861(iii)(1) of the
Act defines HIT as professional services,
including nursing services; training and
education not otherwise covered under
the Durable Medical Equipment (DME)
benefit; remote monitoring; and other
monitoring services. Home infusion
therapy must be furnished by a qualified
HIT supplier and furnished in the
individual’s home. The individual must:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
60799
• Be under the care of an applicable
provider (that is, physician, nurse
practitioner, or physician assistant); and
• Have a plan of care established and
periodically reviewed by a physician in
coordination with the furnishing of
home infusion drugs under Part B, that
prescribes the type, amount, and
duration of infusion therapy services
that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act
requires that a qualified HIT supplier be
accredited by an accrediting
organization (AO) designated by the
Secretary in accordance with section
1834(u)(5) of the Act. Section
1834(u)(5)(A) of the Act identifies
factors for designating AOs and in
reviewing and modifying the list of
designated AOs. These statutory factors
are as follows:
• The ability of the organization to
conduct timely reviews of accreditation
applications.
• The ability of the organization take
into account the capacities of suppliers
located in a rural area (as defined in
section 1886(d)(2)(D) of the Act).
• Whether the organization has
established reasonable fees to be
charged to suppliers applying for
accreditation.
• Such other factors as the Secretary
determines appropriate.
Section 1834(u)(5)(B) of the Act
requires the Secretary to designate AOs
to accredit HIT suppliers furnishing HIT
not later than January 1, 2021. Section
1861(iii)(3)(D) of the Act defines
‘‘qualified home infusion therapy
suppliers’’ as being accredited by a
CMS-approved AO.
In the March 1, 2019 Federal Register,
we published a solicitation notice
entitled, ‘‘Medicare Program;
Solicitation of Independent Accrediting
Organizations To Participate in the
Home Infusion Therapy Supplier
Accreditation Program’’ (84 FR 7057).
This notice informed national AOs that
accredit HIT suppliers of an opportunity
to submit applications to participate in
the HIT supplier accreditation program.
Complete applications will be
considered for the January 1, 2021
designation deadline if received by
February 1, 2020.
Regulations for the approval and
oversight of AOs for HIT organizations
are located at 42 CFR part 488, subpart
L. The requirements for HIT suppliers
are located at 42 CFR part 486, subpart
I.
II. Approval of Accreditation
Organizations
Section 1834(u)(5) of the Act and the
regulations at § 488.1010 require that
our findings concerning review and
E:\FR\FM\28SEN1.SGM
28SEN1
60800
Federal Register / Vol. 85, No. 188 / Monday, September 28, 2020 / Notices
approval of a national AO’s
requirements consider, among other
factors, the applying AO’s requirements
for accreditation; survey procedures;
resources for conducting required
surveys; capacity to furnish information
for use in enforcement activities;
monitoring procedures for provider
entities found not in compliance with
the conditions or requirements; and
ability to provide CMS with the
necessary data.
Section 488.1020(a) requires that we
publish, after receipt of an
organization’s complete application, a
notice identifying the national
accrediting body making the request,
describing the nature of the request, and
providing at least a 30-day public
comment period. In accordance with
§ 488.1010(d), we have 210 days from
the receipt of a complete application to
approve or deny the application.
III. Provisions of the Proposed Notice
In the May 4, 2020 Federal Register
(85 FR 26477), we published a proposed
notice announcing The Compliance
Team’s (TCT’s) request for initial
approval of its Medicare HIT
accreditation program. In that proposed
notice, we detailed our evaluation
criteria. Under section 1834(u)(5) the
Act and in our regulations at § 488.1010,
we conducted a review of TCT’s
Medicare HIT accreditation application
in accordance with the criteria specified
by our regulations, which included, but
are not limited to the following:
• An administrative review of TCT’s:
(1) Corporate policies; (2) financial and
human resources available to
accomplish the proposed surveys; (3)
procedures for training, monitoring, and
evaluation of its home infusion therapy
surveyors; (4) ability to investigate and
respond appropriately to complaints
against accredited home infusion
therapies; and (5) survey review and
decision-making process for
accreditation.
• The ability for TCT to conduct
timely review of accreditation
applications.
• The ability of TCT to take into
account the capacities of suppliers
located in a rural area.
• The comparison of TCT’s Medicare
HIT accreditation program standards to
our current Medicare home infusion
therapy conditions for coverage (CfCs).
• A documentation review of TCT’s
survey process to:
++ Determine the composition of the
survey team, surveyor qualifications,
and TCT’s ability to provide continuing
surveyor training.
++ Compare TCT’s processes,
including periodic resurvey and the
VerDate Sep<11>2014
18:25 Sep 25, 2020
Jkt 250001
ability to investigate and respond
appropriately to complaints against
accredited home infusion therapies.
++ Evaluate TCT’s procedures for
monitoring home infusion therapies it
has found to be out of compliance with
TCT’s program requirements.
++ Assess TCT’s ability to report
deficiencies to the surveyed home
infusion therapy and respond to the
home infusion therapy’s plan of
correction in a timely manner.
++ Establish TCT’s ability to provide
CMS with electronic data and reports
necessary for effective validation and
assessment of the organization’s survey
process.
++ Determine the adequacy of TCT’s
staff and other resources.
++ Confirm TCT’s ability to provide
adequate funding for performing
required surveys.
++ Confirm TCT’s policies with
respect to surveys being unannounced.
++ Review TCT’s policies and
procedures to avoid conflicts of interest,
including the appearance of conflicts of
interest, involving individuals who
conduct surveys or participate in
accreditation decisions.
++ Obtain TCT’s agreement to provide
CMS with a copy of the most current
accreditation survey together with any
other information related to the survey
as we may require, including corrective
action plans.
The May 4, 2020 proposed notice also
solicited public comments regarding
whether TCT’s requirements met or
exceeded the Medicare CfCs for home
infusion therapy. No comments were
received in response to our proposed
notice.
IV. Provisions of the Final Notice
A. Differences Between TCT’s Standards
and Requirements for Accreditation and
Medicare Conditions and Survey
Requirements
We compared TCT’s HIT accreditation
requirements and survey process with
the Medicare CfCs of part 486, subpart
I and the survey and certification
process requirements of part 488,
subpart L. Our review and evaluation of
TCT’s HIT application, which was
conducted as described in section III. of
this final notice, yielded the following
areas where, as of the date of this notice,
TCT has completed revising its
standards and certification processes in
order to meet the condition at:
• § 486.520(b), to address the
requirement of the plan of care must be
established by a physician prescribing
the type, amount and duration for home
infusion therapy.
• § 486.525(a), to include the
language ‘‘must’’ and ‘‘qualified’’ to
PO 00000
Frm 00049
Fmt 4703
Sfmt 9990
meet the requirements for home
infusion suppliers.
• § 486.525(a)(1) through (3) and (b),
to restructure and revise submitted
standard language to meet the
requirements for professional services,
patient training and education, remote
monitoring, and standards of practice.
• § 488.1010(a)(6), to revise TCT’s
procedures for surveys.
B. Term of Approval
As authorized under § 488.1040(a), we
reserve the right to conduct onsite
observations of accrediting organization
operations at any time as part of the
ongoing review and continuing
oversight of an accrediting
organization’s performance. Based on
the review and observations described
in section III. of this final notice, we
have determined that TCT’s
requirements for HIT meet or exceed our
requirements. Therefore, we approve
TCT as a national accreditation
organization for HITs that request
participation in the Medicare program,
effective October 1, 2020 through
October 1, 2024.
IV. Collection of Information
Requirements
This document does not impose
information collection and
requirements, that is, reporting,
recordkeeping or third party disclosure
requirements. Consequently, there is no
need for review by the Office of
Management and Budget under the
authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. Chapter 35).
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Seema Verma, having reviewed and
approved this document, authorizes
Lynette Wilson, who is the Federal
Register Liaison, to electronically sign
this document for purposes of
publication in the Federal Register.
Dated: September 22, 2020.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare
& Medicaid.
[FR Doc. 2020–21260 Filed 9–25–20; 8:45 am]
BILLING CODE 4120–01–P
E:\FR\FM\28SEN1.SGM
28SEN1
Agencies
[Federal Register Volume 85, Number 188 (Monday, September 28, 2020)]
[Notices]
[Pages 60799-60800]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-21260]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3386-FN]
Medicare Program; Approval of Application by The Compliance Team
for Initial CMS-Approval of Its Home Infusion Therapy Accreditation
Program
AGENCY: Centers for Medicare and Medicaid Services, HHS.
ACTION: Final notice.
-----------------------------------------------------------------------
SUMMARY: This final notice announces our decision to approve The
Compliance Team for initial recognition as a national accrediting
organization for home infusion therapy suppliers that wish to
participate in the Medicare program. A home infusion therapy supplier
that participates must meet the Medicare conditions for coverage.
DATES: The approval announced in this final notice takes effect October
1, 2020 through October 1, 2024.
FOR FURTHER INFORMATION CONTACT:
Christina Mister-Ward, (410) 786-2441.
Shannon Freeland, (410) 786-4348.
Lillian Williams, (410) 786-8636.
SUPPLEMENTARY INFORMATION:
I. Background
Home Infusion therapy (HIT) is a treatment option for Medicare
beneficiaries with a wide range of acute and chronic conditions.
Section 5012 of the 21st Century Cures Act (Pub. L. 114-255, enacted on
December 13, 2016) added sections 1861(iii) and 1834(u) to the Social
Security Act (the Act), establishing a new Medicare benefit for HIT
services. Section 1861(iii)(1) of the Act defines HIT as professional
services, including nursing services; training and education not
otherwise covered under the Durable Medical Equipment (DME) benefit;
remote monitoring; and other monitoring services. Home infusion therapy
must be furnished by a qualified HIT supplier and furnished in the
individual's home. The individual must:
Be under the care of an applicable provider (that is,
physician, nurse practitioner, or physician assistant); and
Have a plan of care established and periodically reviewed
by a physician in coordination with the furnishing of home infusion
drugs under Part B, that prescribes the type, amount, and duration of
infusion therapy services that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act requires that a
qualified HIT supplier be accredited by an accrediting organization
(AO) designated by the Secretary in accordance with section 1834(u)(5)
of the Act. Section 1834(u)(5)(A) of the Act identifies factors for
designating AOs and in reviewing and modifying the list of designated
AOs. These statutory factors are as follows:
The ability of the organization to conduct timely reviews
of accreditation applications.
The ability of the organization take into account the
capacities of suppliers located in a rural area (as defined in section
1886(d)(2)(D) of the Act).
Whether the organization has established reasonable fees
to be charged to suppliers applying for accreditation.
Such other factors as the Secretary determines
appropriate.
Section 1834(u)(5)(B) of the Act requires the Secretary to
designate AOs to accredit HIT suppliers furnishing HIT not later than
January 1, 2021. Section 1861(iii)(3)(D) of the Act defines ``qualified
home infusion therapy suppliers'' as being accredited by a CMS-approved
AO.
In the March 1, 2019 Federal Register, we published a solicitation
notice entitled, ``Medicare Program; Solicitation of Independent
Accrediting Organizations To Participate in the Home Infusion Therapy
Supplier Accreditation Program'' (84 FR 7057). This notice informed
national AOs that accredit HIT suppliers of an opportunity to submit
applications to participate in the HIT supplier accreditation program.
Complete applications will be considered for the January 1, 2021
designation deadline if received by February 1, 2020.
Regulations for the approval and oversight of AOs for HIT
organizations are located at 42 CFR part 488, subpart L. The
requirements for HIT suppliers are located at 42 CFR part 486, subpart
I.
II. Approval of Accreditation Organizations
Section 1834(u)(5) of the Act and the regulations at Sec. 488.1010
require that our findings concerning review and
[[Page 60800]]
approval of a national AO's requirements consider, among other factors,
the applying AO's requirements for accreditation; survey procedures;
resources for conducting required surveys; capacity to furnish
information for use in enforcement activities; monitoring procedures
for provider entities found not in compliance with the conditions or
requirements; and ability to provide CMS with the necessary data.
Section 488.1020(a) requires that we publish, after receipt of an
organization's complete application, a notice identifying the national
accrediting body making the request, describing the nature of the
request, and providing at least a 30-day public comment period. In
accordance with Sec. 488.1010(d), we have 210 days from the receipt of
a complete application to approve or deny the application.
III. Provisions of the Proposed Notice
In the May 4, 2020 Federal Register (85 FR 26477), we published a
proposed notice announcing The Compliance Team's (TCT's) request for
initial approval of its Medicare HIT accreditation program. In that
proposed notice, we detailed our evaluation criteria. Under section
1834(u)(5) the Act and in our regulations at Sec. 488.1010, we
conducted a review of TCT's Medicare HIT accreditation application in
accordance with the criteria specified by our regulations, which
included, but are not limited to the following:
An administrative review of TCT's: (1) Corporate policies;
(2) financial and human resources available to accomplish the proposed
surveys; (3) procedures for training, monitoring, and evaluation of its
home infusion therapy surveyors; (4) ability to investigate and respond
appropriately to complaints against accredited home infusion therapies;
and (5) survey review and decision-making process for accreditation.
The ability for TCT to conduct timely review of
accreditation applications.
The ability of TCT to take into account the capacities of
suppliers located in a rural area.
The comparison of TCT's Medicare HIT accreditation program
standards to our current Medicare home infusion therapy conditions for
coverage (CfCs).
A documentation review of TCT's survey process to:
++ Determine the composition of the survey team, surveyor
qualifications, and TCT's ability to provide continuing surveyor
training.
++ Compare TCT's processes, including periodic resurvey and the
ability to investigate and respond appropriately to complaints against
accredited home infusion therapies.
++ Evaluate TCT's procedures for monitoring home infusion therapies
it has found to be out of compliance with TCT's program requirements.
++ Assess TCT's ability to report deficiencies to the surveyed home
infusion therapy and respond to the home infusion therapy's plan of
correction in a timely manner.
++ Establish TCT's ability to provide CMS with electronic data and
reports necessary for effective validation and assessment of the
organization's survey process.
++ Determine the adequacy of TCT's staff and other resources.
++ Confirm TCT's ability to provide adequate funding for performing
required surveys.
++ Confirm TCT's policies with respect to surveys being
unannounced.
++ Review TCT's policies and procedures to avoid conflicts of
interest, including the appearance of conflicts of interest, involving
individuals who conduct surveys or participate in accreditation
decisions.
++ Obtain TCT's agreement to provide CMS with a copy of the most
current accreditation survey together with any other information
related to the survey as we may require, including corrective action
plans.
The May 4, 2020 proposed notice also solicited public comments
regarding whether TCT's requirements met or exceeded the Medicare CfCs
for home infusion therapy. No comments were received in response to our
proposed notice.
IV. Provisions of the Final Notice
A. Differences Between TCT's Standards and Requirements for
Accreditation and Medicare Conditions and Survey Requirements
We compared TCT's HIT accreditation requirements and survey process
with the Medicare CfCs of part 486, subpart I and the survey and
certification process requirements of part 488, subpart L. Our review
and evaluation of TCT's HIT application, which was conducted as
described in section III. of this final notice, yielded the following
areas where, as of the date of this notice, TCT has completed revising
its standards and certification processes in order to meet the
condition at:
Sec. 486.520(b), to address the requirement of the plan
of care must be established by a physician prescribing the type, amount
and duration for home infusion therapy.
Sec. 486.525(a), to include the language ``must'' and
``qualified'' to meet the requirements for home infusion suppliers.
Sec. 486.525(a)(1) through (3) and (b), to restructure
and revise submitted standard language to meet the requirements for
professional services, patient training and education, remote
monitoring, and standards of practice.
Sec. 488.1010(a)(6), to revise TCT's procedures for
surveys.
B. Term of Approval
As authorized under Sec. 488.1040(a), we reserve the right to
conduct onsite observations of accrediting organization operations at
any time as part of the ongoing review and continuing oversight of an
accrediting organization's performance. Based on the review and
observations described in section III. of this final notice, we have
determined that TCT's requirements for HIT meet or exceed our
requirements. Therefore, we approve TCT as a national accreditation
organization for HITs that request participation in the Medicare
program, effective October 1, 2020 through October 1, 2024.
IV. Collection of Information Requirements
This document does not impose information collection and
requirements, that is, reporting, recordkeeping or third party
disclosure requirements. Consequently, there is no need for review by
the Office of Management and Budget under the authority of the
Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35).
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Seema Verma, having reviewed and approved this document,
authorizes Lynette Wilson, who is the Federal Register Liaison, to
electronically sign this document for purposes of publication in the
Federal Register.
Dated: September 22, 2020.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare & Medicaid.
[FR Doc. 2020-21260 Filed 9-25-20; 8:45 am]
BILLING CODE 4120-01-P